Skip to main
SHC

Sotera Health (SHC) Stock Forecast & Price Target

Sotera Health (SHC) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 67%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Sotera Health is a strong competitor in the sterilization services industry with a solid financial foundation and strong partnerships. Despite ongoing legal challenges, their investment in compliance and competitive advantage are expected to result in steady growth and market share gains. Their subsidiaries, Nelson Labs and Nordion, also have significant potential for growth in the coming years and are expected to contribute to Sotera's overall success. While there are concerns about potential margin pressure and performance at Nelson Labs, Sotera's overall outlook remains positive with strong revenue growth and increased guidance for 2025.

Bears say

Sotera Health is a strong company with a focus on safety and strong financials, but faces challenges with supply chain issues and litigation. While they are making progress in addressing these issues, potential changes at the FDA and the need for upgrades to comply with regulations could affect their growth and profitability. Overall, Sotera may face roadblocks in expanding their capacity and could see slower growth in the future. They are still expected to generate positive cash flow and have strong partnerships, but investors should closely monitor any developments in their ongoing legal and regulatory challenges.

Sotera Health (SHC) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 67% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sotera Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sotera Health (SHC) Forecast

Analysts have given Sotera Health (SHC) a Buy based on their latest research and market trends.

According to 6 analysts, Sotera Health (SHC) has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sotera Health (SHC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.